We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued a warning letter to generics firm Bigmar-Bioren SA last month after uncovering significant cGMP deviations at its manufacturing plant in Barbengo, Switzerland.